Salus Scientific Closes Series A Financing to Support Occupational Wellness Platform

August 6, 2026—Salus Scientific Corporation announced the closing of its oversubscribed Series A financing, raising a total of $10.1 million.

ALARA+ Coalition Launches Toolkits to Accelerate Adoption of Enhanced Radiation Protection

August 6, 2026—The Society for Cardiovascular Angiography & Interventions (SCAI) and the Society of Interventional Radiology announced that the release of the ALARA+ (“As Low And As Light As Reasonably Achievable”) Coalition’s resources to help hospital leadership and decisionmakers implement enhanced radiation and occupational safety guidelines for clinicians and staff working in catheterization labs.

Jack Darby Named CEO of Circa Scientific

July 31, 2026—Circa Scientific, Inc., a developer of access technologies for structural heart and electrophysiology procedures, announced the appointment of Jack Darby as Chief Executive Officer.

CroíValve Appoints Jaime Wheeler as Chief Executive Officer

July 31, 2026—CroíValve announced the appointment of Jaime Wheeler as Chief Executive Officer.

VDyne Commences TriNova TTVR System’s TRIVITA US Pivotal Study

July 31, 2026—VDyne Inc. announced that the first patient has been enrolled in the TRIVITA United States investigational device exemption pivotal study of the company’s TriNova transcatheter tricuspid valve replacement (TTVR) system for the treatment for tricuspid regurgitation (TR).

Caristo Diagnostics’ CaRi-Heart Coronary Inflammation Technology Receives FDA De Novo Authorization

July 30, 2026—Caristo Diagnostics announced that the FDA has granted de novo authorization for the company’s CaRi-Heart to quantify coronary inflammation from routine coronary CT angiography (CCTA).

Braun Commences BASKET BALL Trial of a DCB-Only Strategy in Complex CAD

July 28, 2026—B.

Abbott Initiates TREAT TR Postmarket Study of the TriClip TEER System 

July 28, 2026—Abbott announced it has initiated the TREAT TR postmarket study of the company’s TriClip transcatheter edge-to-edge repair (TEER) system for the treatment of tricuspid regurgitation (TR).

Venus Medtech’s PREVAILS Trial for Venus-PowerX TAVR System Completes Enrollment

July 27, 2026—China-based Venus Medtech (Hangzhou) Inc. announced that patient enrollment has been completed in its PREVAILS pivotal trial for the Venus-PowerX transcatheter aortic valve (TAVR) system, which is designed to be 100% retrievable after full deployment.

CryoTherapeutics Commences ICECAP Trial of Localized Cryotherapy for CAD

July 27, 2026—CryoTherapeutics, based in Liège, Belgium, announced the treatment of the first patient in its ICECAP clinical trial of the company’s investigational cryotherapy system.